Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells

PLoS One. 2014 Feb 25;9(2):e89525. doi: 10.1371/journal.pone.0089525. eCollection 2014.

Abstract

Magnesium reduces vascular smooth muscle cell (VSMC) calcification in vitro but the mechanism has not been revealed so far. This work used only slightly increased magnesium levels and aimed at determining: a) whether inhibition of magnesium transport into the cell influences VSMC calcification, b) whether Wnt/β-catenin signaling, a key mediator of osteogenic differentiation, is modified by magnesium and c) whether magnesium can influence already established vascular calcification. Human VSMC incubated with high phosphate (3.3 mM) and moderately elevated magnesium (1.4 mM) significantly reduced VSMC calcification and expression of the osteogenic transcription factors Cbfa-1 and osterix, and up-regulated expression of the natural calcification inhibitors matrix Gla protein (MGP) and osteoprotegerin (OPG). The protective effects of magnesium on calcification and expression of osteogenic markers were no longer observed in VSMC cultured with an inhibitor of cellular magnesium transport (2-aminoethoxy-diphenylborate [2-APB]). High phosphate induced activation of Wnt/β-catenin pathway as demonstrated by the translocation of β-catenin into the nucleus, increased expression of the frizzled-3 gene, and downregulation of Dkk-1 gene, a specific antagonist of the Wnt/β-catenin signaling pathway. The addition of magnesium however inhibited phosphate-induced activation of Wnt/β-catenin signaling pathway. Furthermore, TRPM7 silencing using siRNA resulted in activation of Wnt/β-catenin signaling pathway. Additional experiments were performed to test the ability of magnesium to halt the progression of already established VSMC calcification in vitro. The delayed addition of magnesium decreased calcium content, down-regulated Cbfa-1 and osterix and up-regulated MGP and OPG, when compared with a control group. This effect was not observed when 2-APB was added. In conclusion, magnesium transport through the cell membrane is important to inhibit VSMC calcification in vitro. Inhibition of Wnt/β-catenin by magnesium is one potential intracellular mechanism by which this anti-calcifying effect is achieved.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Boron Compounds / pharmacology
  • Calcium-Binding Proteins / genetics
  • Calcium-Binding Proteins / metabolism
  • Cells, Cultured
  • Extracellular Matrix Proteins / genetics
  • Extracellular Matrix Proteins / metabolism
  • Humans
  • Magnesium / pharmacology*
  • Matrix Gla Protein
  • Muscle, Smooth, Vascular / cytology*
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / metabolism
  • Osteogenesis / drug effects*
  • Osteoprotegerin / genetics
  • Osteoprotegerin / metabolism
  • Protein Serine-Threonine Kinases
  • RNA, Messenger / genetics
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction / drug effects
  • TRPM Cation Channels / antagonists & inhibitors
  • TRPM Cation Channels / genetics
  • TRPM Cation Channels / metabolism
  • Vascular Calcification / drug therapy*
  • Vascular Calcification / metabolism
  • Wnt Proteins / antagonists & inhibitors*
  • Wnt Proteins / genetics
  • Wnt Proteins / metabolism
  • beta Catenin / antagonists & inhibitors*
  • beta Catenin / genetics
  • beta Catenin / metabolism

Substances

  • Boron Compounds
  • Calcium-Binding Proteins
  • Extracellular Matrix Proteins
  • Osteoprotegerin
  • RNA, Messenger
  • TNFRSF11B protein, human
  • TRPM Cation Channels
  • Wnt Proteins
  • beta Catenin
  • 2-aminoethoxydiphenyl borate
  • Protein Serine-Threonine Kinases
  • TRPM7 protein, human
  • Magnesium

Grants and funding

This study was supported by Instituto Carlos III (FIS 07/0287, FIS 07/0315, 010/1311), Consejeria de Salud (JA 0127/2008), a UE Grant from Framework Programme 7 Syskid (FP7-241544), and Consejeria de Innovacion, Ciencia y Empresa (CTS-5205 and CTS-179) of Junta de Andalucia. The study has been also financed in part by Fresenius Medical Care Deutschland GmbH. The external funders (Fresenius Medical Care Deutschland GmbH) participated in part of study design and revision of final version of manuscript. They had no role in data collection, analysis, preparation of manuscript and decision to publish.